Valerio Therapeutics (France) Performance
| ALVIO Stock | 0.14 0.01 6.67% |
Valerio Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The entity has a beta of -0.64, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Valerio Therapeutics are expected to decrease at a much lower rate. During the bear market, Valerio Therapeutics is likely to outperform the market. Use Valerio Therapeutics sortino ratio and the relationship between the downside variance and period momentum indicator , to analyze future returns on Valerio Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Valerio Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Valerio Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Valerio |
Valerio Therapeutics Relative Risk vs. Return Landscape
If you would invest 6.10 in Valerio Therapeutics on October 20, 2025 and sell it today you would earn a total of 7.90 from holding Valerio Therapeutics or generate 129.51% return on investment over 90 days. Valerio Therapeutics is generating 2.3526% of daily returns and assumes 15.8048% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Valerio on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Valerio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Valerio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Valerio Therapeutics, and traders can use it to determine the average amount a Valerio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1489
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ALVIO | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.8 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.35 actual daily | 47 53% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Valerio Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Valerio Therapeutics by adding it to a well-diversified portfolio.
Things to note about Valerio Therapeutics performance evaluation
Checking the ongoing alerts about Valerio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Valerio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Valerio Therapeutics is way too risky over 90 days horizon | |
| Valerio Therapeutics has some characteristics of a very speculative penny stock | |
| Valerio Therapeutics appears to be risky and price may revert if volatility continues |
- Analyzing Valerio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Valerio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Valerio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Valerio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Valerio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Valerio Therapeutics' stock. These opinions can provide insight into Valerio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Valerio Stock Analysis
When running Valerio Therapeutics' price analysis, check to measure Valerio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valerio Therapeutics is operating at the current time. Most of Valerio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Valerio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valerio Therapeutics' price. Additionally, you may evaluate how the addition of Valerio Therapeutics to your portfolios can decrease your overall portfolio volatility.